Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.

35 The phase II study from Harrington et al showed a superiority of lapatinib treatment in combination with chemoradiotherapy in p16-negative patients with locally advanced HNNSC, that nevertheless did not reach statistical significance. 23 Moreover, due to the limited number of patients and the short follow-up period, in the same study it was not possible to evaluate the efficacy of lapatinib in p16-positive (surrogate marker of HPV infection) patients, and further studies are needed to address this point.

also in 111,027 other papers